For the Inventor, By the Inventor

Enter assignee name

Bengaluru, India

Aurigene Discovery Technologies Limited

USPTO Granted Patents = 45

% Expired Patents = 31.1

EPO Patents = 14

Forward Citations = 319

Loading Chart...

Loading Chart...

50 inventors (with patents filed for the assignee):

Muralidhara Ramachandra (19 out of 31 patents)

Pottayil Govindan Nair Sasikumar (15 out of 23 patents)

Seetharamaiah Setty Sudarshan Naremaddepalli (12 out of 19 patents)

4. Susanta Samajdar (12 out of 27 patents)

5. Venkateshwar Rao Gummadi (8 out of 15 patents)

6. Subramanya Hosahalli (7 out of 17 patents)

7. Subhendu Mukherjee (5 out of 11 patents)

8. Pottayil Govindan N Sasikumar (5 out of 7 patents)

9. Ramulu Poddutoori (4 out of 13 patents)

10. Sunil Kumar Panigrahi (4 out of 16 patents)

11. Chetan Pandit (3 out of 10 patents)

12. Rajeev Goswami (3 out of 4 patents)

13. Seetharamaiah Setty S Naremaddepalli (3 out of 4 patents)

14. Dinesh Chikkanna (2 out of 5 patents)

15. Srinivasa Raju Sammeta (2 out of 2 patents)

Core Competencies:

IRAK4 Inhibitors

PRMT5 Inhibitors

Immunomodulators

CD47 Signalling

CDK Inhibitors

Thiadiazole Compounds

Peptidomimetic Compounds

Hematological Disorders

Cyclic Compounds

Small Molecule Inhibitors

Immunosuppression Modulating Compounds

Combination Therapies

45 patents: Sort by Forward Citations

1. 12371426 - Pyridazine derivatives as SMARCA2/4 degraders (2025-07-29),

2. 11691987 - Bicyclic heterocyclyl derivatives as IRAK4 inhibitors (2023-07-04),

3. 11680051 - Crystalline forms of 3-substituted 1,2,4-oxadiazole (2023-06-20),

4. 11542275 - Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors (2023-01-03),

5. 11512060 - 1,2,4-oxadiazole derivatives as immunomodulators (2022-11-29),

6. 11497735 - Conjoint therapies for immunomodulation (2022-11-15),

7. 11497734 - Dual inhibitors of TIM-3 and PD-1 pathways (2022-11-15),

8. 11465976 - 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators (2022-10-11),

9. 11419875 - Compounds and compositions for treating hematological disorders (2022-08-23),

10. 11365205 - Imidazolidin-2-one compounds as PRMT5 modulators (2022-06-21),

11. 11311517 - Combination of small molecule CD-47 inhibitors with other anti-cancer agents (2022-04-26),

12. 11274123 - 1,2,4-oxadiazole compounds as inhibitors of CD47 signalling (2022-03-15),

13. 11229636 - Substituted tetrahydroquinolinone compounds as ROR gamma modulators (2022-01-25),

14. 11186576 - Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors (2021-11-30),

15. 11174232 - Substituted heterocyclyl derivatives as CDK inhibitors (2021-11-16),

Aurigene Discovery Technologies Limited is a biotech company focused on innovative drug discovery and development. With a vast expertise in structure-based drug design, fragment-based drug discovery, and cell-based assays, Aurigene aims to accelerate the discovery of novel therapeutics for a variety of diseases including cancer, inflammation, and metabolic disorders.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

Aurigene Discovery Technologies Limited

45 Patents

#11 in Bengaluru

#46 in India

#15,403 in the World

Bengaluru, India

Aurigene Discovery Technologies Limited

Forward Citations = 319

50 inventors:

Muralidhara Ramachandra (19 out of 31 patents)

Pottayil Govindan Nair Sasikumar (15 out of 23 patents)

Seetharamaiah Setty Sudarshan Naremaddepalli (12 out of 19 patents)

4. Susanta Samajdar (12 out of 27 patents)

5. Venkateshwar Rao Gummadi (8 out of 15 patents)

Please report any incorrect information to [email protected]

Loading…